Key Developments For Allos Therapeutics Inc
Allos Therapeutics Inc (ALTH.O) (Consolidated Issue listed on NASDAQ Global Market)
Allos Therapeutics, Inc. Announces Closing of Public Offering
Allos Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 14,000,000 shares of newly issued common stock at a public offering price of $7.10 per share. The Company received net proceeds from the sale of the shares, after underwriting discounts, commissions and estimated offering expenses, of approximately $93.0 million. Allos has also granted the underwriters a 30-day option to purchase up to an aggregate of 2,100,000 additional shares of common stock to cover over-allotments, if any. Allos currently anticipates using the net proceeds of the offering primarily for activities relating to the commercialization of FOLOTYN (pralatrexate injection), preclinical research and clinical development of FOLOTYN, and for general corporate purposes. J.P. Morgan Securities Inc. and Citigroup Global Markets Inc. acted as joint book-running managers of the offering. Leerink Swann LLC acted as co-lead manager of the offering.
Allos Therapeutics, Inc. Announces Pricing Of Public Offering Of Common Stock
Allos Therapeutics, Inc. announced the pricing of an underwritten public offering of 14,000,000 primary shares of its common stock at a public offering price of $7.10 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $99.4 million. The offering is expected to close on or about October 13, 2009, subject to customary closing conditions. Allos has also granted the underwriters a 30-day option to purchase up to an aggregate of 2,100,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are being sold by Allos. Allos currently anticipates using the net proceeds of the offering primarily for activities relating to the commercialization of FOLOTYN (pralatrexate injection), preclinical research and clinical development of FOLOTYN, and for general corporate purposes. J.P. Morgan Securities Inc. and Citigroup Global Markets Inc. are acting as joint book-running managers of the offering.
Allos Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
Allos Therapeutics, Inc. announced that it is offering to sell, subject to market and other conditions, 11,000,000 primary shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Allos Therapeutics also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 1,650,000 additional primary shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by Allos Therapeutics, with proceeds to be used to support the commercialization of FOLOTYN (pralatrexate injection), preclinical research and clinical development of FOLOTYN, and general corporate purposes. J.P. Morgan Securities Inc. and Citigroup Global Markets, Inc. are acting as joint book-running managers of the proposed offering. Leerink Swann LLC is acting as co-lead manager of the offering. JMP Securities LLC is acting as co-manager of the offering.
Allos Therapeutics, Inc. Secures FDA Approval For FOLOTYNTM
Allos Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for FOLOTYNTM (pralatrexate injection) for use as a single agent for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The Company allos expects to make FOLOTYN available to patients in the U.S. in October.
Allos Therapeutics, Inc. Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN (pralatrexate) For The Treatment of Patients
Allos Therapeutics, Inc. announced that the U.S. Food and Drug Administration`s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). PTCL comprises a biologically diverse group of aggressive blood cancers that has a worse prognosis than most other types of lymphoma, including B-cell lymphoma. If approved, FOLOTYN would be the first drug approved by the FDA for the treatment of relapsed or refractory PTCL.
